Raymond James downgraded Natera to Outperform from Strong Buy with a price target of $85, up from $68.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- Jury rules in favor of Natera in patent infringement lawsuit against CareDx
- CareDx found to have not infringed on one Natera patent, infringed on another
- Wolfe reiterates Outperform on Natera after favorable jury decision
- CareDx weakness attributed to ruling in patent fight
- Natera Acquires Invitae’s Prenatal Screening Business